| SELNET clinical practice guidelines for soft tissue sarcoma and GIST JY Blay, N Hindi, J Bollard, S Aguiar Jr, M Angel, B Araya, R Badilla, ... Cancer treatment reviews 102, 102312, 2022 | 50 | 2022 |
| Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair–related genes L Bruno, A Ostinelli, F Waisberg, D Enrico, C Ponce, S Rivero, A Blanco, ... JCO Precision Oncology 6, e2100140, 2022 | 31 | 2022 |
| Cancer treatment adaptations in the COVID-19 era F Waisberg, D Enrico, M Angel, M Chacón JCO oncology practice 16 (6), 305, 2020 | 31 | 2020 |
| Uncommon subtypes of malignant melanomas: A review based on clinical and molecular perspectives M Chacón, Y Pfluger, M Angel, F Waisberg, D Enrico Cancers 12 (9), 2362, 2020 | 30 | 2020 |
| Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the adjuvant setting: a systematic review and meta-analysis MR Chacón, DH Enrico, J Burton, FD Waisberg, VM Videla JAMA Network Open 1 (8), e185617-e185617, 2018 | 30 | 2018 |
| Efficacy and safety of nivolumab in previously treated patients with non–small-cell lung cancer: real world experience in Argentina C Martin, L Lupinacci, F Perazzo, C Bas, O Carranza, C Puparelli, ... Clinical Lung Cancer 21 (5), e380-e387, 2020 | 24 | 2020 |
| SELNET clinical practice guidelines for bone sarcoma JY Blay, E Palmerini, J Bollard, S Aguiar, M Angel, B Araya, R Badilla, ... Critical Reviews in Oncology/Hematology 174, 103685, 2022 | 19 | 2022 |
| Burnout syndrome in medical oncologists during the COVID-19 pandemic: Argentinian national survey A Guercovich, G Piazzioni, F Waisberg, P Mandó, M Angel ecancermedicalscience 15, 2021 | 14 | 2021 |
| Implementation of a virtual multicenter gastrointestinal tumor board to reduce cancer disparities in Argentina F Esteso, NS Tissera, JM O'Connor, R Luca, E Huertas, FS Loria, ... World Journal of Clinical Oncology 13 (6), 423, 2022 | 11 | 2022 |
| Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review D Enrico, F Waisberg, J Burton, P Mandó, M Chacon Critical Reviews in Oncology/Hematology 160, 103296, 2021 | 11 | 2021 |
| Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project) MO Angel, RC Bonadio, G Harada, F Waisberg, D Enrico, O Arrieta, ... ESMO open 5 (6), e000988, 2020 | 11 | 2020 |
| CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression. LS Lapuchesky, M Bortz, F Waisberg, DH Enrico, LI Bruno, CA Ostinelli, ... Journal of Clinical Oncology 40 (16_suppl), 1056-1056, 2022 | 9 | 2022 |
| HER2-directed therapy in advanced breast cancer: benefits and risks P Mandó, F Waisberg, R Pasquinelli, S Rivero, A Ostinelli, F Perazzo OncoTargets and therapy, 115-132, 2023 | 7 | 2023 |
| Sarcoma European and Latin American Network (SELNET) recommendations on prioritization in sarcoma care during the COVID‐19 pandemic J Martin‐Broto, N Hindi, S Aguiar Jr, R Badilla‐González, V Castro‐Oliden, ... The Oncologist 25 (10), e1562-e1573, 2020 | 7 | 2020 |
| The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review D Narvaez, J Nadal, A Nervo, MV Costanzo, C Paletta, FE Petracci, ... Cancers 16 (2), 396, 2024 | 6 | 2024 |
| First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study A Falco, M Leiva, A Blanco, G Cefarelli, A Rodriguez, J Melo, F Cayol, ... World Journal of Clinical Oncology 13 (2), 147, 2022 | 6 | 2022 |
| Overcoming resistance to osimertinib by T790M loss and C797S acquisition using gefitinib in a patient with EGFR-mutant NSCLC: a case report D Enrico, F Tsou, G Catani, C Pupareli, MR Girotti, DEU Alvarez, ... JTO Clinical and Research Reports 4 (2), 100456, 2023 | 5 | 2023 |
| Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: a systematic review F Waisberg, C Lopez, D Enrico, A Rodriguez, I Hirsch, J Burton, P Mandó, ... Critical Reviews in Oncology/Hematology 176, 103747, 2022 | 5 | 2022 |
| P2. 18-04 real-world study on efficacy of first-line nivolumab+ ipilimumab in unresectable malignant pleural mesothelioma (ImmunoMeso) ED Aguirre, DH Enrico, NS Tissera, F Tsou, C Pupareli, D Peralta, ... Journal of Thoracic Oncology 18 (11), S382, 2023 | 2 | 2023 |
| 442P Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001) FD Waisberg, P Mando, C Almada, N Kassis, AC Mainella, L Cermignani, ... Annals of Oncology 34, S367, 2023 | 1 | 2023 |
